PDCD1 and hepatocellular carcinoma: Another retrospective study involving patients with established recurrent HCC who underwent either RFA alone or RFA coupled with anti-PD-1 therapy exhibited a notably higher 1-year recurrence-free survival rate in the group receiving anti-PD-1 plus RFA (32.5% vs. 10.0%, p = 0.008) [121].